Research & Development
Policy & Regulation
Trends & Finance
$54B U.S. IVD market to grow 2% per year for five years: Kalorama
Test makers will need to get creative for growth, and they can do so by focusing on a few growth-rich segments, such as point-of-care products and tissue diagnostics
October 11, 2022
SARS-CoV-2 molecular tests highly accurate in Canadian study
The diagnostic sensitivity of these molecular tests suggests that one negative test result can effectively rule out SARS-CoV-2 infection for most patients, the researchers said.
October 12, 2022
Contract manufacturing market for IVD products to reach $16.1B in 2022: Kalorama
Evolving trends in IVD contract manufacturing will result in developed economies retaining more than three-fourths of the total global demand.
October 4, 2022
NanoDx, SkyWater launch nano biosensor
The companies said that as a result of the development, NanoDx is ready to prepare and submit the product for review by the U.S. Food and Drug Administration (FDA) with the aim of eventually commercializing a product based on the technology.
August 25, 2022
Huron Digital taps Audil Virk as president
Virk has executive leadership and operational experience in general management, strategy, product development, and technology commercialization, Huron said.
April 14, 2022
Babson Diagnostics receives CAP accreditation
Babson’s lab in Austin first received CAP accreditation in 2020. In the renewal application, the company for the first time demonstrated proficiency for its proprietary testing techniques, which run broad blood panels using one-tenth the sample volume of traditional blood tests. The company has developed miniaturized assays to optimize each microsample.
March 17, 2022
Dr. Fauci invokes Yogi Berra to describe emerging infectious disease challenge
C2N Diagnostics launching next-generation blood test for Alzheimer's disease detection
Thermo Fisher Scientific introduces digital PCR liquid-biopsy assays for academic, clinical research
Thermo Fisher Scientific updates Applied Biosystems genetic analyzers to comply with IVDR
Aspira announces commercial launch of blood-based ovarian cancer risk assay
MDxHealth sees Medicare delay for prostate cancer risk test, reduces 2022 revenue guide
Lucence, Waseda University partner on liquid biopsy test
Lucence believes the technology could be used in potential applications in early cancer detection and disease monitoring. Lucence plans to commercialize the liquid biopsy platform from its CLIA-licensed laboratory in Palo Alto.
March 23, 2021
Page 1 of 1